1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

04 Oct 2023
Admin
News Article

Pfizer launches Rimegepant in Hong Kong, first market in Asia for migraine management

Rimegepant is launched in over 39 markets to date, including in the United States, and in the European Union and the United Kingdom

US-based pharmaceutical company Pfizer has announced the availability of Rimegepant in Hong Kong, the first market in Asia, a calcitonin gene-related peptide (CGRP) receptor antagonist for migraine management. There are approximately 12.5% of people living with migraine in Hong Kong and it is one of the leading causes of disability worldwide. Migraine disproportionately affects women, occurring three to four times more often in women than in men.

Rimegepant targets a key component of migraine by blocking CGRP (calcitonin gene-related peptide) receptors. The increase of CGRP leads to blood vessels dilation, causing migraine attack. ^[10] CGRP receptor antagonists work by blocking CGRP receptors, thereby inhibiting the biologic activity of the endogenous CGRP neuropeptide.

Results from the Phase 3 study published in Lancet demonstrated that a single dose of Rimegepant provided superior reduction in pain and associated symptoms of migraine at two hours compared to placebo. Another study, also published in Lancet, demonstrated that Rimegepant, when taken every other day, provided superior reduction in the number of days per month with migraine in Weeks 9 –12 of the 12-week administration period when compared to placebo.

Rimegepant is launched in over 39 markets to date, including in the United States, and in the European Union and the United Kingdom. Additional regulatory applications are under review around the world.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!